Related references
Note: Only part of the references are listed.French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides)
Benjamin Terrier et al.
ORPHANET JOURNAL OF RARE DISEASES (2020)
Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial
Seerapani Gopaluni et al.
TRIALS (2017)
EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
M. Yates et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Multilevel airway stenosis in patients with granulomatosis with polyangiitis (Wegener's)
Elizabeth Guardiani et al.
AMERICAN JOURNAL OF OTOLARYNGOLOGY (2015)
Biological drugs in ANCA-associated vasculitis
Pamela M. K. Lutalo et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2015)
An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's)
Carol A. Langford et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis
L. Guillevin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides
J. C. Jennette et al.
ARTHRITIS AND RHEUMATISM (2013)
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis.
John H. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis.
Rachel B. Jones et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force
C. Mukhtyar et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Share Paper
